Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

TEPEZZA: A Compelling Value Proposition Addressing a Significant Unmet Need Unmet Need No prior treatments for thyroid eye disease Rare Disease U.S. addressable incidence of 15K to 20K patients (1) (1) Horizon estimate of patients eligible for TEPEZZA each year. HI HORIZON Efficacy 82.9 percent achieved proptosis reduction of ≥2mm Acute Treatment 6-month course of therapy with long-term durability Safety Significant benefits outweigh manageable risks Compelling Value Proposition 21

View entire presentation